What question did this study set out to answer?

To design and synthesize a novel quinoline-thiazolidinedione hybrid (compound 7) that acts as a selective PPARγ modulator to lower blood glucose without inducing full-agonist side effects like hepatotoxicity.

June 1, 2025Scientific ReportsOpen Access

Design and synthesis of a novel quinoline thiazolidinedione hybrid as a potential antidiabetic PPARγ modulator

View Full Paper

Ask AI

Bookmark

To design and synthesize a novel quinoline-thiazolidinedione hybrid (compound 7) that acts as a selective PPARγ modulator to lower blood glucose without inducing full-agonist side effects like hepatotoxicity.
Synthesized (Z)-5-benzylidene-3-((2-chloroquinolin-3-yl)methyl)thiazolidine-2,4-dione (compound 7) and administered a daily single oral dose over 15 days.
Assessed in vivo antidiabetic efficacy, PPARγ activation relative to pioglitazone, serum liver enzymes (ALT and AST), and histopathology of hepatic and pancreatic tissues.
Performed computational docking in the PPARγ ligand-binding domain and metabolic stability modeling.
Compound 7 lowered blood glucose levels by 22.33% after 15 days of treatment and increased PPARγ expression to 75% of the activation level induced by pioglitazone.
Liver enzyme levels were significantly lower than with pioglitazone (ALT: 147.4 ± 4.2 IU/L; AST: 229.9 ± 2.7 IU/L), demonstrating protective effects on hepatic and pancreatic tissues.
Computational modeling showed central positioning within the PPARγ ligand-binding domain without undergoing thiazolidinedione ring hydrolysis or generating toxic metabolites.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical study demonstrates reduced blood glucose and lower hepatotoxicity in animal models, suggesting a safer selective PPARγ modulator for diabetes.

Cite This Study

Ibrahim et al. (2025) studied this question.

synapsesocial.com/papers/6a0dbae29a2918c675a4fbf3 https://doi.org/10.1038/s41598-025-03387-9

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates reduced blood glucose and lower hepatotoxicity in animal models, suggesting a safer selective PPARγ modulator for diabetes.

Design and synthesis of a novel quinoline thiazolidinedione hybrid as a potential antidiabetic PPARγ modulator

Key Points

Discussion

Implication

Cite This Study

Design and synthesis of a novel quinoline thiazolidinedione hybrid as a potential antidiabetic PPARγ modulator

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider